AMA announces new CPT codes for bivalent COVID-19 vaccine boosters
The American Medical Association (AMA) released eight Current Procedural Terminology (CPT®) codes for Moderna and Pfizer-BioNTech’s updated COVID-19 vaccine booster doses. These boosters are adapted for the BA.4 and BA.5 omicron subvariants.
CPT codes 91312, 91313, 0124A, and 0134A are effective for use immediately. On August 31, the FDA authorized the Moderna booster for use in those aged 18 or older and the Pfizer-BioNTech booster for use in those aged 12 or older.
CPT codes 91314, 91315, 0144A, and 0154A will not be effective until the FDA authorizes the updated boosters for children. Moderna is seeking authorization for use in children aged 6 to 11 years, whereas Pfizer-BioNTech needs authorization for children between 5 and 11 years old.
The descriptors for the new codes are as follows:
Moderna bivalent booster – 18 years and older
91313: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use
0134A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose
Moderna bivalent booster – 6 years through 11 years
91314: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use
0144A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose
Pfizer-BioNTech bivalent booster – 12 years and older
91312: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
0124A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose
Pfizer-BioNTech bivalent booster – 5 years through 11 years
91315: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
0154A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose
The AMA offers a resource to help find the appropriate CPT code combination for type and dose of COVID-19 vaccines. Additional information from can be found in the COVID-19 Provider Toolkit.
Editor's note: Find more NAHRI resources on COVID-19 vaccines here.